Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

Generic Semaglutide From Aspen Wins Approval in South Africa and Brazil

Aspen wins generic semaglutide approval in South Africa and Brazil, with launches planned in coming months. Read what this means for diabetes care.
Generic Semaglutide From Aspen Wins Approval in South Africa and Brazil
Image | Kateryna | Adobe Stock/2010706923

Aspen Pharmacare plans to launch generic semaglutide in South Africa, Brazil and Canada within months, following regulatory approvals across all three markets.

The group announced the South African and Brazilian approvals on 11 November. These follow Canadian authorisation in July 2026.

Continue reading with a Health Matters subscription

Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

SubscribeLog in

Not ready to subscribe? Get Health Matters Weekly free: the week’s top healthcare headlines every Friday.

More from Health Matters

12.11.2026

Learn why the Diabetes Alliance is launching a framework to track diabetes care commitments as South Africa's 2027 NCD targets rapidly approach.

12.11.2026

Learn why Viatris and Innovata are seeking leave to appeal the ARV tender ruling that set aside their TLD contracts, and what it means for supply.

11.11.2026

Public medicine shortages leave patients without treatment as unpaid provincial bills disrupt supplies. Read why financial accountability matters.